Boston Scientific stock faces weaker Q4 outlook after slow growth
Published on 11/05/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth pressure meets pipeline progress
- Third-quarter net sales rose 1.5 percent year over year to 5.138 billion US dollars.
- Boston Scientific expects fourth-quarter sales to decline 1 percent to 3 percent year over year.
- New device clearances, a Heartflow collaboration and clinical development support the longer-term portfolio.
Boston Scientific lowered its near-term growth outlook after third-quarter sales increased 1.5 percent year over year to 5.138 billion US dollars. The company shared the results on October 28, while its pipeline continued to expand through regulatory clearances and partnerships.
Management expects fourth-quarter reported and organic sales to decline between 1 percent and 3 percent from the prior-year period. Full-year 2026 reported sales growth is expected at 4.25 percent, while organic growth is projected at 3.75 percent. Adjusted earnings per share guidance stands at 3.16 to 3.18 US dollars for the year and 0.77 to 0.79 US dollars for the fourth quarter.
Pipeline adds longer-term support
According to Boston Scientific, the company received FDA 510(k) clearance for the Navigator Flex ureteral access sheath, the LithoVue Elite single-use ureteroscope with temperature sensing and expanded sizes of the SEISMIQ intravascular lithotripsy catheter. Boston Scientific also began enrollment in the Elite AF trial for its next-generation WATCHMAN platform.
The company entered a strategic collaboration with Heartflow to advance AI-powered, CT-guided planning for percutaneous coronary intervention. The American Medical Association also assigned Category I CPT codes for selected renal denervation and implantable tibial nerve stimulation devices effective in January 2028.
Stock trades on Lang & Schwarz
Boston Scientific stock traded at 40.73 euros on Lang & Schwarz at 15:41 CET on Thursday, November 5, 2026; the real-time quote of Boston Scientific stock is available here.
For investors, the weaker fourth-quarter outlook points to continued execution pressure, while product approvals, clinical trials and the Heartflow collaboration provide potential support for the longer-term growth strategy.
The S&P 500 provides the relevant market backdrop for Boston Scientific stock: Current market reports.
More news and analyses on Boston Scientific stock are available on the Boston Scientific stock topic page.
Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Exchange: NYSE
- Lang & Schwarz price: 40.73 euros on November 5, 2026, at 15:41 CET
- Third-quarter net sales: 5.138 billion US dollars
- Full-year organic sales outlook: 3.75 percent growth
